We are attaching herewith proceedings of 43rd Annual General Meeting of the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivanza Biosciences held its 43rd Annual General Meeting on Thursday, September 25, 2025, at 3:15 PM via video conferencing, lasting only seven minutes. The Chairman (Mr. Mehta J.A.) and CFO (Mr. Bhatt J.R.) were present along with other directors, the company secretary, and the secretarial auditor. The CFO briefed members on the company's financial performance and future outlook, though no shareholder questions were raised during the meeting. Six items of business were put to vote, including adoption of FY2024-25 audited financial statements, re-appointment of a director, regularization of two additional directors (one independent and one non-executive), appointment of the secretarial auditor for five years from FY2025-26, and alteration of the object clause of the Memorandum of Association. E-voting was open from September 22-24, 2025, and results are to be announced within 48 hours.
This is a routine procedural filing — no immediate impact on shareholders. Investors should watch for the voting results within 48 hours, particularly on the MOA object clause alteration (which could signal a shift in business focus) and the new director appointments. The absence of shareholder questions and the very short meeting duration suggest no contentious issues were discussed.